A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome.

• Published in: PLOS Neglected Tropical Diseases
• Main Authors: Koichiro Suemori, Masayuki Saijo, Atsushi Yamanaka, Daisuke Himeji, Masafumi Kawamura, Takashi Haku, Michihiro Hidaka, Chinatsu Kamikokuryo, Yasuyuki Kakihana, Taichi Azuma, Katsuto Takenaka, Toru Takahashi, Akitsugu Furumoto, Toshiyuki Ishimaru, Masayuki Ishida, Masahiko Kaneko, Norimitsu Kadowaki, Kenichi Ikeda, Shigetoshi Sakabe, Tomohiro Taniguchi, Hiroki Ohge, Takeshi Kurosu, Tomoki Yoshikawa, Masayuki Shimojima, Masaki Yasukawa
• Format: Article in Journal/Newspaper
• Language: English
• Published: Public Library of Science (PLoS) 2021
• Subjects: Arctic medicine. Tropical medicine; RC955-962; Public aspects of medicine; RA1-1270; Arctic
• Online Access: https://doi.org/10.1371/journal.pntd.0009103; https://doaj.org/article/920dd2f0bda94c97829881ddaf926a42

Severe fever with thrombocytopenia syndrome (SFTS) is a bunyavirus infection with high mortality. Favipiravir has shown effectiveness in preventing and treating SFTS virus (SFTSV) infection in animal models. A multicenter non-randomized, uncontrolled single arm trial was conducted to collect data on the safety and the effectiveness of favipiravir in treatment of SFTS patients. All participants received favipiravir orally (first-day loading dose of 1800 mg twice a day followed by 800 mg twice a day for 7-14 days in total). SFTSV RT-PCR and biochemistry tests were performed at designated time points. Outcomes were 28-day mortality, clinical improvement, viral load evolution, and adverse events (AEs). Twenty-six patients were enrolled, of whom 23 were analyzed. Four of these 23 patients died of multi-organ failure within one week (28-day mortality rate: 17.3%). Oral favipiravir was well tolerated in the surviving patients. AEs (abnormal hepatic function and insomnia) occurred in about 20% of the patients. Clinical symptoms improved in all patients who survived from a median of day 2 to day10. SFTSV RNA levels in the patients who died were significantly higher than those in the survivors (p = 0.0029). No viral genomes were detectable in the surviving patients a median of 8 days after favipiravir administration. The 28-day mortality rate in this study was lower than those of the previous studies in Japan. The high frequency of hepatic dysfunction as an AE was observed. However, it was unclear whether this was merely a side effect of favipiravir, because liver disorders are commonly seen in SFTS patients. The results of this trial support the effectiveness of favipiravir for patients with SFTS.